Jupiter Neurosciences, Inc. (JUNS)

US — Healthcare Sector

Peers: SKYE SER ALGS ABVC XFOR KZR FGEN GNTA MRSN GRCE

Automate Your Wheel Strategy on JUNS

With Tiblio's Option Bot, you can configure your own wheel strategy including JUNS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol JUNS
Rev/Share 0.0
Book/Share 0.0017
PB 349.7839
Debt/Equity 3.1418
CurrentRatio 0.6481
ROIC -31.7829

MktCap 20311549.0
FreeCF/Share -0.198
PFCF -3.0129
PE -2.6434
Debt/Assets 0.07
DivYield 0
ROE -3.5197

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 3
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

JUNS
Published: January 27, 2026 by: Accesswire
Sentiment: Neutral

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

image for news Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

JUNS
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio

image for news Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

JUNS
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation

About Jupiter Neurosciences, Inc. (JUNS)

IPO Date 2022-01-18
Website https://www.jupiterorphan.com
Industry Biotechnology
CEO Christer Rosen
Employees 4

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.